Flomoxef

Last updated
Flomoxef
Flomoxef.png
Clinical data
Trade names Flumarin
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
  • (6R,7R)-7-[[2-(Difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C15H18F2N6O7S2
Molar mass 496.46 g·mol−1
3D model (JSmol)
Melting point 82.5 to 87.5 °C (180.5 to 189.5 °F)
  • CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSc3nnnn3CCO)C(=O)O)NC(=O)CSC(F)F
  • InChI=1S/C15H18F2N6O7S2/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27)/t12-,15+/m1/s1 X mark.svgN
  • Key:UHRBTBZOWWGKMK-DOMZBBRYSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Flomoxef is an oxacephem antibiotic that was developed by Shionogi.

It has been classified either as a second-generation [1] or fourth-generation cephalosporin. [2]

It was patented in 1982 and approved for medical use in 1988 under the trade name Flumarin. [3]

Related Research Articles

<span class="mw-page-title-main">Trazodone</span> Chemical compound, antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and difficulties with sleep. The medication is taken orally.

<span class="mw-page-title-main">Histidine decarboxylase</span> Enzyme that converts histidine to histamine

The enzyme histidine decarboxylase is transcribed on chromosome 15, region 21.2, and catalyzes the decarboxylation of histidine to form histamine. In mammals, histamine is an important biogenic amine with regulatory roles in neurotransmission, gastric acid secretion and immune response. Histidine decarboxylase is the sole member of the histamine synthesis pathway, producing histamine in a one-step reaction. Histamine cannot be generated by any other known enzyme. HDC is therefore the primary source of histamine in most mammals and eukaryotes. The enzyme employs a pyridoxal 5'-phosphate (PLP) cofactor, in similarity to many amino acid decarboxylases. Eukaryotes, as well as gram-negative bacteria share a common HDC, while gram-positive bacteria employ an evolutionarily unrelated pyruvoyl-dependent HDC. In humans, histidine decarboxylase is encoded by the HDC gene.

Haplogroup P also known as P-P295 and K2b2 is a Y-chromosome DNA haplogroup in human genetics. P-P295 is a branch of K2b, which is a branch of Haplogroup K2 (K-M526).

<span class="mw-page-title-main">Diphenylpyraline</span> Chemical compound

Diphenylpyraline is a first-generation antihistamine with anticholinergic effects of the diphenylpiperidine class. It is marketed in Europe for the treatment of allergies. DPP has also been found to act as a dopamine reuptake inhibitor and produces hyperactivity in rodents. It has been shown to be useful in the treatment of Parkinsonism.

<i>meta</i>-Chlorophenylpiperazine Stimulant

meta-Chlorophenylpiperazine (mCPP) is a psychoactive drug of the phenylpiperazine class. It was initially developed in the late-1970s and used in scientific research before being sold as a designer drug in the mid-2000s. It has been detected in pills touted as legal alternatives to illicit stimulants in New Zealand and pills sold as "ecstasy" in Europe and the United States.

<span class="mw-page-title-main">Melperone</span> Antipsychotic drug

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

<span class="mw-page-title-main">PHKA2</span> Protein-coding gene in the species Homo sapiens

Phosphorylase b kinase regulatory subunit alpha, liver isoform is an enzyme that in humans is encoded by the PHKA2 gene.

<span class="mw-page-title-main">RFX2</span> Protein-coding gene in the species Homo sapiens

DNA-binding protein RFX2 is a protein that in humans is encoded by the RFX2 gene.

<span class="mw-page-title-main">Zinc transporter 4</span>

Zinc transporter 4 is a protein that in humans is encoded by the SLC30A4 gene.

<span class="mw-page-title-main">KCNK5</span>

Potassium channel subfamily K member 5 is a protein that in humans is encoded by the KCNK5 gene.

<span class="mw-page-title-main">SGK2</span> Protein-coding gene in the species Homo sapiens

Serine/threonine-protein kinase Sgk2 is an enzyme that in humans is encoded by the SGK2 gene.

<span class="mw-page-title-main">ADCY4</span> Protein-coding gene in the species Homo sapiens

Adenylyl cyclase type 4 is an enzyme that in humans is encoded by the ADCY4 gene.

<span class="mw-page-title-main">KCNK15</span>

Potassium channel subfamily K member 15 is a protein that in humans is encoded by the KCNK15 gene.

<span class="mw-page-title-main">KCNH6</span> Protein-coding gene in the species Homo sapiens

Potassium voltage-gated channel subfamily H member 6 is a protein that in humans is encoded by the KCNH6 gene. The protein encoded by this gene is a voltage-gated potassium channel subunit.

<span class="mw-page-title-main">Oxacephem</span> Class of pharmaceutical drugs

An oxacephem is a β-lactam molecule similar to a cephem, but with an oxygen substituted for the sulfur. They are synthetic compounds not seen in nature, generally used as β-lactam antibiotics. Examples include Latamoxef and Flomoxef.

<span class="mw-page-title-main">Tiospirone</span> Pharmaceutical drug

Tiospirone (BMY-13,859), also sometimes called tiaspirone or tiosperone, is an atypical antipsychotic of the azapirone class. It was investigated as a treatment for schizophrenia in the late 1980s and was found to have an effectiveness equivalent to those of typical antipsychotics in clinical trials but without causing extrapyramidal side effects. However, development was halted and it was not marketed. Perospirone, another azapirone derivative with antipsychotic properties, was synthesized and assayed several years after tiospirone. It was found to be both more potent and more selective in comparison and was commercialized instead.

<span class="mw-page-title-main">Roxindole</span> Dopaminergic & serotonergic drug developed for schizophrenia treatment

Roxindole (EMD-49,980) is a dopaminergic and serotonergic drug which was originally developed by Merck KGaA for the treatment of schizophrenia. In clinical trials its antipsychotic efficacy was only modest but it was unexpectedly found to produce potent and rapid antidepressant and anxiolytic effects. As a result, roxindole was further researched for the treatment of depression instead. It has also been investigated as a therapy for Parkinson's disease and prolactinoma.

<span class="mw-page-title-main">IRX2</span> Protein-coding gene in the species Homo sapiens

Iroquois-class homeodomain protein IRX-2, also known as Iroquois homeobox protein 2, is a protein that in humans is encoded by the IRX2 gene.

<span class="mw-page-title-main">IRX6</span> Protein-coding gene in the species Homo sapiens

Iroquois-class homeodomain protein IRX-6, also known as Iroquois homeobox protein 6, is a protein that in humans is encoded by the IRX6 gene.

Activated protein C–protein C inhibitor (APC-PCI) is a complex of activated protein C (APC) and protein C inhibitor (PCI). It has been measured in coagulation testing to evaluate coagulation, thrombosis, and other cardiovascular complications. It is a marker of thrombin generation and indicates hypercoagulability. The half-life of APC-PCI is either 40 minutes or 140 minutes.

References

  1. Masuda Z, Kurosaki Y, Ishino K, Yamauchi K, Sano S (April 2008). "Pharmacokinetic analysis of flomoxef in children undergoing cardiopulmonary bypass and modified ultrafiltration". Gen Thorac Cardiovasc Surg. 56 (4): 163–9. doi:10.1007/s11748-007-0208-5. PMID   18401677. S2CID   23845740.
  2. Ito M, Ishigami T (1991). "The meaning of the development of flomoxef and clinical experience in Japan". Infection. 19 Suppl 5: S253–7. doi:10.1007/bf01645536. PMID   1783441. S2CID   25339977.
  3. Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN   9783527607495.